CareDx, Inc. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
CareDx reported Q2 2026 revenue of $132M (52% YoY growth) driven by Testing Services revenue of $100M (+61% YoY, 58,000 tests). The company divested its Lab Products business to Eurobio Scientific on June 30, 2026, recognizing a $113M gain. Full-year 2026 revenue guidance raised to $490–$500M (from $447–$465M) and adjusted EBITDA guidance raised to $66–$78M (from $43–$57M). Non-GAAP diluted EPS was $0.37 vs. $0.10 in Q2 2025.
Why this rating
52% revenue growth and upward guidance revision are material for a ~$1B company; divestiture streamlines focus but $113M gain is one-time. Operational momentum and EBITDA expansion are substantive, though organic testing growth of 17% units is moderate.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.